Skip to main content

Table 1 Demographics and biomarker values for the diagnostic groupsa

From: CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer’s disease as an indicator of tau phosphorylation

 

EOAD

LOAD

MCI

SCD

PD

HC

P

N

71

34

11

17

45

32

 

Sex (M/F)

25/46

17/17

6/5

4/13

18/27

12/20

.412b

Agec

58.0 (54.0–62.0)

77.0 (73.0–80.0)

68.0 (59.0–75.0)

67.0 (61.0–73.0)

68.0 (60.0–74.5)

66.5 (62.0–68.0)

.000d

MMSEe

16.0 (13.0–20.0)

19.0 (16.0–21.0)

25.0 (24.0–26.0)

29.0 (25.5–29.0)

28.0 (27.0–30.0)

.000d

CDR 0/0.5/1/2/3e

0/20/33/15/3

0/13/15/6/0

0/10/1/0/0

2/15/0/0/0

15/17/0/0/0

.000f

CSF Aβ42 (pg/mL)

326.8 (258.6–488.2)

401.3 (239.6–587.3)

737.5 (445.9–806.9)

990.3 (904.3–1043.5)

774.4 (595.2–967.2)

1078.0 (982.4–1297.3)

.000d

CSF T-tau (pg/mL)

534.3 (386.2–732.9)

442.6 (326.3–598.2)

283.6 (203.7–490.8)

321.9 (252.1–335.9)

159.4 (116.9–215.8)

203.3 (147.1–295.9)

.000d

CSF P-tau181 (pg/mL)

77.2 (53.9–106.0)

69.9 (44.1–89.7)

54.6 (40.1–83.3)

51.5 (41.1–60.4)

34.8 (25.5–43.6)

40.3 (32.1–54.6)

.000d

CSF α-syn (pg/mL)

754.2 (526.7–1163.9)

834.8 (586.5–1330.3)

889.5 (628.7–1079.5)

880.4 (689.5–1154.8)

590.9 (420.0–842.3)

669.8 (506.8–973.3)

.007d

Amyloid-PET (+/−)g

50/1

18/10

1/4

1/12

1/21

.000b

  1. Abbreviations: EOAD early-onset Alzheimer’s disease, LOAD late-onset Alzheimer’s disease, MCI mild cognitive impairment, SCD subjective cognitive decline, PD Parkinson’s disease, HC healthy control, M male, F female, MMSE Mini-Mental State Examination, CDR Clinical Dementia Rating, CSF cerebrospinal fluid, 42 amyloid-β 1-42; T-tau total tau; P-tau181 phosphorylated tau 181, α-syn α-synuclein, FBB-PET18F-florbetaben positron emission tomography
  2. aData are shown as median (interquartile) unless otherwise indicated
  3. bChi-square test
  4. cExcluding EOAD and LOAD, the P value is 0.425
  5. dKruskal-Wallis test
  6. ePD was not performed the cognitive assessment
  7. fFisher’s exact test
  8. gA limited number of individuals were available for amyloid-PET scan